非小细胞肺癌患者EML4-ALK融合基因突变对个体化靶向治疗预后的影响

doi:10.3969/j.issn.1671-7171.2021.10.012

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1264 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨非小细胞肺癌(NSCLC)患者棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶(EML4-ALK)融合基因突变对个体化靶向治疗预后的影响。【方法】选取2016年2月至2018年2月不本院标保存的NSCLC组织标本110例,采用实时荧光定量PCR检测EML4-ALK融合基因突变情况,分析其对患者个体化靶向治疗预后的影响。【结果】共有13例患者检出EML4-ALK融合基因突变,突变率为11.82%(13/110)。其中年龄＜60岁、TNM分期Ⅲ期患者EML4-ALK融合基因突变率分别为19.23%(10/52)和23.81%(10/42),明显高于年龄≥60岁、Ⅰ～Ⅱ期患者(P<0.05);EML4-ALK融合基因突变与未突变患者中位生存期分别为14.00个月(95%CI:11.71～16.29)和13.00个月(95%CI:12.39～13.61),两组相比较差异无显著性(P>0.05)。【结论】NSCLC患者EML4-ALK融合基因突变与患者年龄、TNM分期有一定关系,但对个体化靶向治疗的预后无明显影响。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	白雪梅
	郭炫
	赵新汉
	赵永华

关键词 ：癌,非小细胞肺, 抗肿瘤药, 基因, 预后

Abstract：【Objective】To investigate the mutation of echinoderms microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene in patients with non-small cell lung cancer (NSCLC) and explore its impact on the prognosis of individualized targeted therapy. 【Methods】A total of 110 NSCLC tissue specimens preserved in our hospital from February 2016 to February 2018 were selected. The mutation of EML4-ALK fusion gene was detected by real-time fluorescence quantitative PCR. The effect of the mutation on individualized targeted therapy were analyzed. 【Results】The mutation of EML4-ALK fusion gene was detected in 13 cases, the mutation rate was 11.82% (13/110). Of which, the mutation rates of EML4-ALK fusion gene were 19.23% and 23.81% in patients aged < 60 years and TNM stage Ⅲ,respectively, which were significantly higher than those in patients aged ≥ 60 years and stage Ⅰ-Ⅱ(P<0.05); The median survival time of EML4-ALK fusion gene mutation and non-mutation patients was 14.00 months (95%CI:11.71-16.29) and 13.00 months (95%CI:12.39-13.61), there was no significant difference (P> 0.05). 【Conclusion】The mutation of EML4-ALK fusion gene in NSCLC patients is related to patient's age and TNM stage, while it has no significant effect on the prognosis of individualized targeted therapy.

Key words： Carcinoma, Non-Small-Cell Lung Antineoplastic Agents Genes Prognosis

收稿日期: 2020-07-20

中图分类号:

R734.2

通讯作者: *E-mail:296402945@qq.com

引用本文:

白雪梅, 郭炫, 赵新汉, 赵永华. 非小细胞肺癌患者EML4-ALK融合基因突变对个体化靶向治疗预后的影响[J]. 医学临床研究, 2021, 38(10): 1483-1485.
BAI Xue-mei, GUO Xuan, ZHAO Xin-han, et al. Mutation and Significance of EML4-ALK Fusion Gene in NSCLC Patients. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1483-1485.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.10.012 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I10/1483

[1] 徐利芬,陈佳,龙昭玲,宋翼.非小细胞肺癌患者表皮生长因子受体和棘皮动物微管相关蛋白样4-间变性淋巴瘤激酶与病理特征的相关性[J].中华老年医学杂志,2016,35(11):1192-1195.
[2] 徐爱茹,马为.ALK融合基因阳性的晚期非小细胞肺癌靶向治疗进展[J].现代肿瘤医学,2019,27(3):529-533.
[3] 唐艳萍,谭晓玉,蔡政民,等.非小细胞肺癌表皮生长因子受体基因突变和 EM L4-ALK 融合基因表达的研究[J].检验医学与临床,2016,13(24):3458-3460.
[4] 俞晓燕.非小细胞肺癌胸水样本不同预处理方式对EML4_ALK融合基因RT-PCR法检测的影响[J].医药前沿,2017,7(24):369-371.
[5] ANDREIA TERESO,LUíS CARRETO,MANUELA BAPTISTA,et al.Interstitial lung disease induced by crizotinib in non-small-cell lung cancer.[J].Acta Med Port,2019,32(3):236-239.
[6] ZHANG ML,WANG Q,DING Y,et al.CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer[J].Thoraci Oncol,2018,13(11):1792-1797.
[7] CAMIDGE D R, KIM H R, AHN M J, et al. Brigatinib versus crizotinib in alk-positive non-small-cell lung cancer[J].N Engl J Med,2018;379(21):2027-2039.
[8] TAN S, SUN D, PU W, et al. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer[J].Mol Cancer, 2018,17(1):138-140.
[9] XU C W, WANG W X, CHEN Y P, et al. Simultaneous VENTANA IHC and RT-PCR testing of ALK status in Chinese non-small cell lung cancer patients and response to crizotinib[J].J Transl Med,2018,16(1):93-96.
[10] XU Y, ZHANG F, PAN X, et al. Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance[J].Cancer Commun (Lond),2018,38(1):19-22.
[11] MELLAS N,HIJRI F,BENBRAHIM Z,et al.Crizotinib in non-small cell lung cancer[J].J Thoracic Oncology,2018,13(11):1792-1797.
[12] DAVID M STRAUGHAN,SAID C AZOURY,VIVEK SHUKLA.Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer[J].Current drug targets,2016,17(6):739-745.
[13] CAMIDGE D R, KIM H R, AHN M J, et al. Brigatinib versus crizotinib in advanced alk inhibitor-naive alk-positive non-small cell lung cancer: second interim analysis of the phase Ⅲ Alta-1L trial[J].J Clin Oncol,2020,38(31):3592-3603.